Larimar Therapeutics (STU:ZA71) Debt-to-Equity : 0.02 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Debt-to-Equity?

Larimar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.76 Mil. Larimar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €4.16 Mil. Larimar Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €212.38 Mil. Larimar Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Larimar Therapeutics's Debt-to-Equity or its related term are showing as below:

STU:ZA71' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14 Med: 0.07 Max: 0.11
Current: 0.02

During the past 5 years, the highest Debt-to-Equity Ratio of Larimar Therapeutics was 0.11. The lowest was -0.14. And the median was 0.07.

STU:ZA71's Debt-to-Equity is ranked better than
87.64% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:ZA71: 0.02

Larimar Therapeutics Debt-to-Equity Historical Data

The historical data trend for Larimar Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Debt-to-Equity Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.14

0.07

0.09

0.05

0.07

Larimar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.06	0.07	0.02

Competitive Comparison of Larimar Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Larimar Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Debt-to-Equity falls into.

Larimar Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Larimar Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.768	+	4.318)	/	74.937
	=	0.07

Larimar Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.759	+	4.158)	/	212.376
	=	0.02

Larimar Therapeutics (STU:ZA71) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Larimar Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (STU:ZA71) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics (STU:ZA71) Headlines

No Headlines